NLS Pharmaceutics and Kadimastem Reveal Hong Kong Patent for Cell-Selection and Enrichment Technology in IsletRx for Diabetes Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 04 2025
0mins
Should l Buy ?
Source: Newsfilter
Patent Grant in Hong Kong: Kadimastem Ltd. has received a patent in Hong Kong for its cell selection and enrichment technology, enhancing the global intellectual property protection for its diabetes treatment candidate, IsletRx, which aims to potentially cure insulin-dependent diabetes.
Significance of the Hong Kong Market: The patent is crucial for Kadimastem's strategy as Hong Kong serves as a key market for diabetes treatment and a gateway to Mainland China, facilitating future clinical collaborations and commercialization efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
